857290-04-1Relevant articles and documents
N-(Pyridin-2-yl) arylsulfonamide inhibitors of 11β-hydroxysteroid dehydrogenase type 1: Strategies to eliminate reactive metabolites
Nair, Sajiv K.,Matthews, Jean J.,Cripps, Stephan J.,Cheng, Hengmiao,Hoffman, Jacqui E.,Smith, Christopher,Kupchinsky, Stanley,Siu, Michael,Taylor, Wendy D.,Wang, Yong,Johnson, Theodore O.,Dress, Klaus R.,Edwards, Martin P.,Zhou, Sue,Hosea, Natilie A.,Lapaglia, Amy,Kang, Ping,Castro, Arturo,Ermolieff, Jacques,Fanjul, Andrea,Vogel, Jennifer E.,Rejto, Paul,Dalvie, Deepak
, p. 2344 - 2348 (2013/05/09)
N-(Pyridin-2-yl) arylsulfonamides 1 and 2 (PF-915275) were identified as potent inhibitors of 11β-hydroxysteroid dehydrogenase type 1. A screen for bioactivation revealed that these compounds formed glutathione conjugates. This communication presents the results of a risk benefit analysis carried out to progress 2 (PF-915275) to a clinical study and the strategies used to eliminate reactive metabolites in this series of inhibitors. Based on the proposed mechanism of bioactivation and structure-activity relationships, design efforts led to N-(pyridin-2-yl) arylsulfonamides such as 18 and 20 that maintained potent 11β-hydroxysteroid dehydrogenase type 1 activity, showed exquisite pharmacokinetic profiles, and were negative in the reactive metabolite assay.
Amino heterocyclyl inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
-
Page/Page column 50, (2010/02/12)
The present invention relates to compounds with the formula (I), or a pharmaceutically acceptable salt thereof: The invention also relates to pharmaceutical compositions comprising the compounds of formula (I) or formula (II) and methods of treating a condition that is mediated by the modulation of 11-β-hsd-1, the method comprising administering to a mammal an effective amount of a compound of formula (I) or formula (II).